GlobeNewswire by notified

Sequana Medical to present at Jefferies London Healthcare Conference

Share


Ghent, Belgium8 November 2022Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies London Healthcare Conference, taking place from 15 to 17 November 2022.

The Company will provide an update on its alfapump® program, which has recently reported positive primary endpoint data from the North American pivotal POSEIDON study in recurrent or refractory ascites due to liver cirrhosis, enabling the filing of a Pre-Market Approval (PMA) application with the FDA, planned for H2 2023. The Company will also provide an update on DSR® (Direct Sodium Removal), its disease-modifying drug program for the treatment of heart failure, for which a US randomized controlled Phase 1b/2a clinical study is planned to begin in H1 2023.

Details company presentation with live webcast

  • Thursday, 17 November 2022 at 10:55 am GMT / 11:55 am CET
  • To register for the webcast, click here
  • The presentation and a replay of the webcast will be available on Sequana Medical's Investors website shortly after the event

Registered investors can request a one-on-one meeting with Sequana Medical management via the online meeting platform of the conference or by contacting the Company at IR@sequanamedical.com.

For more information, please contact:

Sequana Medical

Lies Vanneste
Director Investor Relations
E: IR@sequanamedical.com
T: +32 (0)498 053579

Optimum Strategic Communications
Mary Clark, Nick Bastin, Vici Rabbetts
E: Sequana@optimumcomms.com
T: +44 (0)7931 500 066

About Sequana Medical

Sequana Medical NV is a pioneer in treating drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. Fluid overload is a well-recognized problem in these growing diseases, causing severe problems for the large number of patients for whom current medicines are no longer effective. These patients can have up to 15 liters of extra fluid in their bodies, causing major medical issues including increased mortality, repeated hospitalizations, severe pain, difficult breathing and restricted mobility that severely impacts daily life.

alfapump® and DSR® are Sequana Medical’s proprietary platforms that work with the body to remove this excess fluid, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems. Sequana Medical is listed on Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com.

Important Regulatory Disclaimers

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. DSR therapy is currently not approved for clinical research in the United States or Canada. There is no link between DSR therapy and ongoing investigations with the alfapump system in Europe, the United States or Canada.

Note:alfapump® is a registered trademark. DSR® is a registered trademark in the Benelux, China, the EU, United Kingdom, and Hong Kong.

Forward-looking statements

This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

DNO Initiates Share Buyback Program8.12.2022 20:47:01 CET | Press release

Oslo, 8 December 2022 – DNO ASA, the Norwegian oil and gas operator (the "Company"), today announced the initiation of a share buyback program (the "Program") through which the Company will repurchase up to 53,107,326 shares, representing approximately five percent of total shares outstanding, for a maximum total consideration of USD 80 million. The Program will be conducted in accordance with article 5 of the Market Abuse Regulation (EU) No 596/2014, as adopted in the Norwegian Securities Trading Act of 2007, ancillary regulations and the Oslo Stock Exchange's Guidelines for buyback programmes and price stabilisation of February 2021. Buyback transactions will be executed at market prices on the Oslo Stock Exchange. The Program will be managed by Arctic Securities AS, which will make its trading decisions in relation to the Program independently of the Company; this may result in DNO acquiring shares through periods where the Company otherwise would have been restricted from doing so.

Park Place Technologies Acquires CentricsIT Global Services Division8.12.2022 20:35:38 CET | Press release

Purchase Strengthens Park Place as Global Leader for all IT Infrastructure Solutions, as Economy and Skills Gap Challenges Impact Global Business. CLEVELAND, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Park Place Technologies, the leading global data center and networking optimization firm, has acquired the TPM and Professional Services assets of CentricsIT, an IT services provider based in Atlanta, Georgia. The demand for Professional Services is growing globally, driven by economic conditions and skills gaps. Park Place’s Professional Services offering will benefit from the acquisition with greater capabilities in IMAC, ITAD, Remote Hands, and deployment services, including cabling, wi-fi surveys, data center installs and refreshes, and network installations. Park Place clients will benefit from a state-of-the-art Professional Services portal developed by CentricsIT that provides real-time project status, reporting, and collaboration tools. Park Place’s Project Management Office function will

Lumina Datamatics Acquires UK-based Sunrise Setting Ltd.8.12.2022 20:15:35 CET | Press release

MILTON KEYNES, United Kingdom, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Lumina Datamatics UK Ltd. signed a definitive agreement to acquire a controlling stake in UK-based Sunrise Setting Ltd., a boutique company based in Brixham, UK, supporting academic and other publishers including non-publisher organizations to produce more than 500 publications each year. “The acquisition of Sunrise Setting Ltd. deepens our commitment to our current customers, and also fits with our strategic growth plan. Sunrise Setting Ltd.’s customers will benefit greatly from our broad range of publishing and technology solutions. The depth and experience of Sunrise Setting Ltd. will enhance Lumina Datamatics’ presence in the UK and EU regions and will help us gain a competitive advantage in the publishing space,” said Sameer Kanodia, Managing Director & CEO of Lumina Datamatics. “There is clear alignment with our company offerings and we are looking forward to taking advantage of the synergies resulting from our coll

BioGX Launches 'pixl™' Portable qPCR Platform Ex-US With Expanded Test Menu for Infectious Diseases8.12.2022 20:00:00 CET | Press release

BIRMINGHAM, Ala., Dec. 08, 2022 (GLOBE NEWSWIRE) -- BioGX, a global provider of easy molecular diagnostic solutions since 2007, announced the Ex-US commercial release of its portable pixl™ qPCR real-time PCR platform for use with BioGX CE-IVD marked assays, enabling global access and complementing the recent US FDA EUA expanded use of Xfree™ COVID-19 Direct RT-PCR on the pixl. The pixl instrument is a benchtop 4-channel, 16-well, RT-PCR instrument that supports rapid turnaround times for batches of up to 16 samples, with integrated results interpretation on a device with the compact footprint of a touchpad. "pixl, combined with our unique Xfree chemistry, offers a low-cost direct-sample-to-answer PCR solution on a portable, compact device. pixl will provide broader access to clinical laboratories for decentralized PCR testing, enabling faster, better, low-cost near-patient molecular diagnostics," said Shazi Iqbal, Ph.D., CEO of BioGX. This platform was previously CE-IVD marked and can

Notification under Chapter 9, Section 10 of the Finnish Securities Market Act: holdings of The Goldman Sachs Group, Inc. in Nokia Corporation exceeded 5%8.12.2022 19:00:00 CET | Press release

Notification under Chapter 9, Section 10 of the Finnish Securities Market Act: holdings of The Goldman Sachs Group, Inc. in Nokia Corporation exceeded 5% Nokia Corporation Stock Exchange Release 8 December 2022 at 20:00 EET Notification under Chapter 9, Section 10 of the Finnish Securities Market Act: holdings of The Goldman Sachs Group, Inc. in Nokia Corporation exceeded 5% According to a notification received under Chapter 9, Section 5 of the Finnish Securities Market Act (FSMA) by Nokia Corporation, the direct and indirect holdings of The Goldman Sachs Group, Inc. in Nokia have on 2 December 2022 exceeded 5% of the total number of shares and voting rights of Nokia. According to the notification received by Nokia, the holdings of The Goldman Sachs Group, Inc. in Nokia on 2 December 2022, directly and through its controlled undertakings and funds was equivalent to a total of 293,966,891 shares, corresponding to approximately 5.22% of the total number of shares and voting rights of Nok